万泰生物涨超6%，九价HPV疫苗首次获得批签发证明

Core Viewpoint - Wantai Biological Pharmacy's nine-valent HPV vaccine has received the biological product batch release certificate, marking its official market launch, which is expected to enhance the company's revenue and profit growth potential [1] Group 1: Company Developments - Wantai Biological's stock price surged over 6%, reaching 61.08 yuan, with trading volume expanding to nearly 700 million yuan [1] - The nine-valent HPV vaccine produced by Wantai's wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has been approved for market release [1] - The launch of the nine-valent HPV vaccine will enrich and optimize the company's product lineup, strengthening its market position and competitive ability [1]